Progress in Clinical and Regulatory Milestones
Significant achievements in clinical trials, including presenting positive data from the PIK3CA wild-type cohort of the VICTORIA-one trial, and FDA's acceptance of the NDA under the real-time oncology review program.
Strong Financial Position
Completion of concurrent offerings resulting in net proceeds of approximately $287 million and an increase in the term loan facility to $500 million, providing substantial financial flexibility.
Positive Clinical Trial Results
In the VICTORIA-one trial, the triplet therapy showed a 7.3-month incremental improvement in median PFS, with hazard ratios more favorable than previously reported.
Solid Market Potential
With a total addressable market estimated at $5 billion to $6 billion, potential peak revenues for Get It Solicit are projected at $2.5 billion to $3 billion.
Progress in Commercial Launch Preparations
Significant progress in building the organization and systems required for a potential launch, alongside positive feedback from key opinion leaders and decision-makers.